These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 38464280)
1. PTEN loss in glioma cell lines leads to increased extracellular vesicles biogenesis and PD-L1 cargo in a PI3K-dependent manner. Sanchez JC; Pierpont TM; Argueta-Zamora D; Wilson K; August A; Cerione RA bioRxiv; 2024 Mar; ():. PubMed ID: 38464280 [TBL] [Abstract][Full Text] [Related]
2. Extracellular vesicles produced by bone marrow mesenchymal stem cells overexpressing programmed death-ligand 1 ameliorate dextran sodium sulfate-induced ulcerative colitis in rats by regulating Th17/Treg cell balance through PTEN/PI3K/AKT/mTOR axis. He H; Chen Q; Fan H; Leng XY; Zhu F; Gao F; Zhou Q; Dong Y; Yang J J Gastroenterol Hepatol; 2022 Dec; 37(12):2243-2254. PubMed ID: 36044618 [TBL] [Abstract][Full Text] [Related]
3. mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma. Han K; Zhang Y J Cancer Res Ther; 2019; 15(4):914-920. PubMed ID: 31436252 [TBL] [Abstract][Full Text] [Related]
4. Superinduction of immunosuppressive glioblastoma extracellular vesicles by IFN-γ through PD-L1 and IDO1. Jung MY; Aibaidula A; Brown DA; Himes BT; Cumba Garcia LM; Parney IF Neurooncol Adv; 2022; 4(1):vdac017. PubMed ID: 35990703 [TBL] [Abstract][Full Text] [Related]
5. Beta cell extracellular vesicle PD-L1 as a novel regulator of CD8+ T cell activity and biomarker during the evolution of Type 1 Diabetes. Rao C; Cater DT; Roy S; Xu J; Olivera AG; Evans-Molina C; Piganelli JD; Eizirik DL; Mirmira RG; Sims EK bioRxiv; 2024 Sep; ():. PubMed ID: 39345410 [TBL] [Abstract][Full Text] [Related]
6. Extracellular vesicles containing PD-L1 contribute to CD8+ T-cell immune suppression and predict poor outcomes in small cell lung cancer. Dou X; Hua Y; Chen Z; Chao F; Li M Clin Exp Immunol; 2022 May; 207(3):307-317. PubMed ID: 35553630 [TBL] [Abstract][Full Text] [Related]
7. PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition. Cretella D; Digiacomo G; Giovannetti E; Cavazzoni A Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31500143 [TBL] [Abstract][Full Text] [Related]
8. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Martin AM; Nirschl TR; Nirschl CJ; Francica BJ; Kochel CM; van Bokhoven A; Meeker AK; Lucia MS; Anders RA; DeMarzo AM; Drake CG Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):325-32. PubMed ID: 26260996 [TBL] [Abstract][Full Text] [Related]
9. Chemerin Reactivates PTEN and Suppresses PD-L1 in Tumor Cells via Modulation of a Novel CMKLR1-mediated Signaling Cascade. Rennier K; Shin WJ; Krug E; Virdi G; Pachynski RK Clin Cancer Res; 2020 Sep; 26(18):5019-5035. PubMed ID: 32605911 [TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression in triple-negative breast cancer. Mittendorf EA; Philips AV; Meric-Bernstam F; Qiao N; Wu Y; Harrington S; Su X; Wang Y; Gonzalez-Angulo AM; Akcakanat A; Chawla A; Curran M; Hwu P; Sharma P; Litton JK; Molldrem JJ; Alatrash G Cancer Immunol Res; 2014 Apr; 2(4):361-70. PubMed ID: 24764583 [TBL] [Abstract][Full Text] [Related]
11. Hepatitis B virus-triggered PTEN/β-catenin/c-Myc signaling enhances PD-L1 expression to promote immune evasion. Sun Y; Yu M; Qu M; Ma Y; Zheng D; Yue Y; Guo S; Tang L; Li G; Zheng W; Wang M; Guo D; Li C Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G162-G173. PubMed ID: 31604033 [TBL] [Abstract][Full Text] [Related]
12. A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway. Zhao L; Li C; Liu F; Zhao Y; Liu J; Hua Y; Liu J; Huang J; Ge C Onco Targets Ther; 2017; 10():2115-2126. PubMed ID: 28442920 [TBL] [Abstract][Full Text] [Related]
13. Extracellular Vesicles From Gastric Cancer Cells Induce PD-L1 Expression on Neutrophils to Suppress T-Cell Immunity. Shi Y; Zhang J; Mao Z; Jiang H; Liu W; Shi H; Ji R; Xu W; Qian H; Zhang X Front Oncol; 2020; 10():629. PubMed ID: 32477934 [TBL] [Abstract][Full Text] [Related]
14. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1. Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569 [TBL] [Abstract][Full Text] [Related]
15. Roles of PTEN inactivation and PD-1/PD-L1 activation in esophageal squamous cell carcinoma. Qiu R; Wang W; Li J; Wang Y Mol Biol Rep; 2022 Jul; 49(7):6633-6645. PubMed ID: 35301651 [TBL] [Abstract][Full Text] [Related]
16. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy. Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036 [TBL] [Abstract][Full Text] [Related]
17. The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction. Himes BT; Peterson TE; de Mooij T; Garcia LMC; Jung MY; Uhm S; Yan D; Tyson J; Jin-Lee HJ; Parney D; Abukhadra Y; Gustafson MP; Dietz AB; Johnson AJ; Dong H; Maus RL; Markovic S; Lucien F; Parney IF Neuro Oncol; 2020 Jul; 22(7):967-978. PubMed ID: 32080744 [TBL] [Abstract][Full Text] [Related]
18. Expression of phosphatase and tensin homolog and programmed cell death ligand 1 in adenosquamous carcinoma of the lung. Hlaing AM; Furusato B; Udo E; Kitamura Y; Souda M; Masutani M; Fukuoka J Biochem Biophys Res Commun; 2018 Sep; 503(4):2764-2769. PubMed ID: 30100056 [TBL] [Abstract][Full Text] [Related]
19. Interferon-γ upregulates Δ42PD1 expression on human monocytes via the PI3K/AKT pathway. Cheng L; Tang X; Xu L; Zhang L; Shi H; Peng Q; Zhao F; Zhou Y; He Y; Wang H; Zhou B; Gao Z; Chen Z Immunobiology; 2019 May; 224(3):388-396. PubMed ID: 30846331 [TBL] [Abstract][Full Text] [Related]
20. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]